A using test for four continuous weeks of C-271 in babies
- Conditions
- ot applicable
- Registration Number
- JPRN-UMIN000038263
- Lead Sponsor
- Inforward, inc EBISU skin research center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Not provided
1)Premature babies. 2)Subjects with birth weight <2,500g. 3)Subjects who have severe eczema infantile. 4)Subjects who have skin symptom such as atopic dermatitis. 5)Subjects who have trauma on the part that uses the test sample. 6)Subjects who have possibility to be exposed to many quantity of sunlight during implementing the test. 7)Subjects who are participating in clinical tests and use tests that apply cosmetic, quasi-drugs and others. 8)Subjects who have allergic symptoms against external medicine, cosmetic, quasi-drugs and others in the past. 9)Subjects who have medical history of serious liver dysfuction, kidney dysfuction and myocardial infarction. 10)Subject who are visiting the hospital regulary for receiving the medical treatment due to the diseases. 11)Subjects who have their family they are working at cosmetic companies and pharmaceutical companies. 12)Others, subjects who have been determined that he/she is ineligible by investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes over time of the systemic skin, between screening visit and after four weeks visit, observed by the Investigators, such as dryness or scale, desquamation, erythema, papules, scratch mark, feeling of stimulation and pruritus.
- Secondary Outcome Measures
Name Time Method * Changes over time of the systemic skin, between screening visit and after two weeks visit, observed by the Investigators, such as dryness or scale, desquamation, erythema, papules, scratch mark, feeling of stimulation and pruritus. * Changes over time of the quantity of stratum corneum water content and transepidermal water loss between screening visit, after two weeks visit and after four weeks visit.